← Eichor
Condition: Relapsed And Refractory Acute Myeloid Leukemia Rr Aml Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed And Refractory Acute Myeloid Leukemia Rr Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Hangzhou Polymed Biopharmaceuticals, Inc. · NCT07137637Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Keystone Nano, Inc · NCT04716452Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06125652Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
NA · 1 location(s) · Huai'an First People's Hospital · NCT06328179
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.